Amarin Corp Plc (AMRN)

[FishyFingers]

These comments made by the CEO in the recent conference call bear repeating:

"In a subgroup analysis of patients with elevated triglyceride levels and low HDL cholesterol an even more substantial 53% reduction in major coronary events was observed compared to statin’s alone. We don't need Vascepa to lower cardiovascular events by 53% to be successful in REDUCE-IT and we now have the published differences between JELIS and REDUCE-IT still the JELIS study highlights the potential therapeutic power of EPA. Also in JELIS note that while patients were studied for five years, there was a significant slip between the active and control arm of the study that occurred at an average of less than a year and a half of patient treatment.

We are blinded to the efficacy results in REDUCE-IT and accordingly we're planning for REDUCE-IT to continue through completion in 2017. However, when the independent data monitoring committee in 2015 looks at the REDUCE-IT study interim efficacy results as provided under the protocol, if the results are comparable to JELIS the committee could elect to stop the study earlier due to overwhelming efficacy, potentially leading to an opportunity to seek approval for expanded indication for Vascepa earlier than expected, if REDUCE-IT is as successful as we believe that it's positioned to be, the opportunity is much larger than typical Phase III results. We do not believe that the magnitude of this opportunity is currently reflected in our stock price."

Evidently neither do the Baker Bros and all the other smart money that has been piling into the company recently.

http://seekingalpha.com/article/2970586-amarins-amrn-ceo-john-thero-on-q4-2014-results-earnings-call-transcript?part=single